Skip to main content
TECON BIOLOGY Co.LTD logo

TECON BIOLOGY Co.LTD — Investor Relations & Filings

Ticker · 002100 ISIN · CNE000001PZ9 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,493 across all filing types
Latest filing 2024-04-28 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002100

About TECON BIOLOGY Co.LTD

https://www.tcsw.com.cn

TECON BIOLOGY Co.LTD operates an integrated industrial chain focused on animal health and nutrition. The company specializes in the research, development, and manufacturing of veterinary biological products, including a comprehensive range of vaccines and diagnostic reagents for livestock. Its operations encompass the production of high-quality animal feed and the management of large-scale breeding programs, with a primary focus on pig farming and meat processing. By leveraging advanced biotechnology and standardized production systems, the company provides comprehensive solutions for livestock management and food safety. Key activities include the formulation of specialized animal nutrition products and the implementation of rigorous biosecurity protocols across its facilities to ensure the quality and reliability of its agricultural outputs.

Recent filings

Filing Released Lang Actions
董事会对独立董事独立性评估的专项意见
Regulatory Filings Classification · 95% confidence The document is a special report on the independence of the company's independent directors, referencing regulatory rules about independent directors and their independence evaluation. It is a formal announcement by the board confirming compliance with independence requirements. The document is short (606 characters) and does not contain financial data, earnings, or detailed management discussion. It is not an annual or interim report, nor an earnings release. It is not a proxy statement or voting result. It is a regulatory compliance announcement related to governance but does not detail governance structure or compensation. It fits best as a Regulatory Filing (RNS) because it is a compliance disclosure that does not fit other specific categories.
2024-04-28 Chinese
高管人员绩效考核及薪酬管理办法
Remuneration Information Classification · 95% confidence The document is titled '高管人员绩效考核及薪酬管理办法' which translates to 'Senior Management Performance Assessment and Compensation Management Measures'. It details the principles, structure, and procedures for determining and managing the compensation and performance evaluation of senior executives. There is no indication of financial statements, audit results, voting results, or regulatory filings. The content focuses on management policies related to remuneration and performance assessment of executives, which aligns with remuneration information filings. The document is not a report or announcement of a report but a detailed policy document on executive compensation.
2024-04-28 Chinese
2023年年度报告
Annual Report Classification · 100% confidence The document is titled as the "2023 年年度报告全文" which translates to "2023 Annual Report Full Text" for Tian Kang Biology Co., Ltd. It contains detailed financial data, management discussion and analysis, company overview, accounting policies, and comprehensive financial indicators for the full fiscal year 2023. The document length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. It includes sections typical of an annual report such as company information, financial data, management discussion, and analysis. There is no indication that this is merely an announcement or a certification. Therefore, this document fits the definition of an Annual Report (10-K). FY 2023
2024-04-28 Chinese
2023年度监事会工作报告
Management Reports Classification · 95% confidence The document is titled as the "2023年度监事会工作报告" which translates to the "2023 Supervisory Board Work Report". It details the supervisory board's activities, meetings, oversight of financial reports, internal controls, and corporate governance during the year 2023. It includes opinions on financial statements, internal controls, related party transactions, and compliance with laws and regulations. The document is a comprehensive report from the supervisory board on their work and oversight for the year, which aligns with a Management Reports (MDA) filing type. It is not an announcement or a brief summary but a detailed report on management oversight and company operations. The document length is 3298 characters, which is relatively short but contains substantive content and detailed supervisory opinions, not just an announcement or certification. Therefore, the best classification is Management Reports (MDA).
2024-04-28 Chinese
关于2023年度计提存货跌价准备的公告
Regulatory Filings Classification · 95% confidence The document is an announcement by Tian Kang Biological Co., Ltd. regarding the provision for inventory impairment for the fiscal year 2023. It details the amount of inventory write-downs, the accounting standards applied, and the impact on the company's 2023 profit. The document includes board and supervisory committee approvals and states that the matter will be submitted to the shareholders' meeting for approval. The document length is 1648 characters, which is relatively short and primarily serves as an announcement of a specific accounting provision rather than a full financial report. It does not contain comprehensive financial statements or detailed financial analysis typical of an Annual Report (10-K) or Interim Report (IR). It is also not a certification or regulatory compliance filing. Therefore, this document fits best as a Regulatory Filing (RNS) because it is a formal disclosure of a significant accounting estimate adjustment and related board decisions, but not a full report or presentation.
2024-04-28 Chinese
关于前期会计差错更正后的财务报表和相关附注
Annual Report Classification · 95% confidence The document is a detailed financial disclosure from Tian Kang Bio Co., Ltd. It includes corrected financial statements for the year 2022, such as consolidated and parent company balance sheets, profit and loss statements, cash flow statements, and changes in equity. The document references corrections due to prior accounting errors and cites relevant accounting standards and regulatory disclosure rules. The length is substantial (15,000 characters), and it contains actual financial data and analysis, not just an announcement or certification. This matches the characteristics of an Annual Report (10-K) or a similar comprehensive financial report. Given the detailed financial statements and notes, it is best classified as an Annual Report (10-K). FY 2022
2024-04-28 Chinese

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.